Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters.
about
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesTwelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation.Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligoNatural killer T cells in advanced melanoma patients treated with tremelimumabThe effects of zoledronate on monocyte-derived dendritic cells from melanoma patients differ depending on the clinical stage of the diseaseIrradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines.Microenvironment and tumor progression of melanoma: new therapeutic prospectives.Dendritic cells and pluripotency: unlikely allies in the pursuit of immunotherapy.Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation.Necroptotic cell death in anti-cancer therapy.Cancer Vaccines in Ovarian Cancer: How Can We Improve?CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma.Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma
P2860
Q26772715-5822790F-FA16-4DAA-91BE-89450F69D790Q30846001-1B3D1402-52F0-4303-BD7A-95D86661657CQ34032559-C0DFBF06-EF9D-419E-A70E-6017ABF80A82Q34352772-59089CEB-9DC7-4563-8A66-AC07FC7F8E98Q35027661-6CB6E7F9-7025-44F9-A5AA-EB806C155C08Q35886565-9AA01EF8-1352-40B8-957F-8C2DD252F20CQ36710917-EF5F433A-AB9B-40D1-B60F-2B45FBCA1374Q36972613-F8BF9E50-28E5-47F7-A6D1-7B2DDA427DF2Q37142487-89FB57AF-2C34-47FE-AA01-5B98A68E2DD5Q38049368-FC75EF87-5B41-4993-900B-3383870F99DDQ38453644-F3BE05E0-CDF1-4F0E-AE42-CD6AC801AD86Q38927132-ACD29126-68A3-46E6-B9CC-B10AD6778B97Q47659073-FE8D8C96-1834-4DA6-B0B1-30BDDE3DF083Q54385315-57AD77D2-B6A7-4F47-A66B-3437D9C83C87Q54586145-183D3052-9A85-4978-8846-64F47D48FA16Q59135320-CFB4E50C-EE18-4FA5-8BA7-0BDF1BCF8DDE
P2860
Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dendritic cell vaccination in ...... ffects and vaccine parameters.
@en
Dendritic cell vaccination in ...... ffects and vaccine parameters.
@nl
type
label
Dendritic cell vaccination in ...... ffects and vaccine parameters.
@en
Dendritic cell vaccination in ...... ffects and vaccine parameters.
@nl
prefLabel
Dendritic cell vaccination in ...... ffects and vaccine parameters.
@en
Dendritic cell vaccination in ...... ffects and vaccine parameters.
@nl
P2093
P1476
Dendritic cell vaccination in ...... ffects and vaccine parameters.
@en
P2093
Noriaki Nakai
Norito Katoh
Saburo Kishimoto
P2860
P304
P356
10.1111/J.1755-148X.2010.00736.X
P577
2010-07-27T00:00:00Z